Crescendo Biologics secures $32M and announces expansion of CB307 Phase 1b trial in PSMA+ solid tumours

Crescendo Biologics, a clinical stage immuno-oncology company, has secured an additional $32 million in funding. This capital infusion was made possible through the support of all major existing investors and new investor Kreos Capital. In conjunction with this exciting news, Crescendo has announced its plans to expand the Phase 1b trial of their lead program CB307 in PSMA+ solid tumors by intro..